2020 Year in Review
2020 has been quite a year! Each year, we strive to provide you with a more innovative, simplified, and seamless early phase drug development journey. And the past 12 months have been no exception.
Up Close and Personal with Dr. Lynne Le Sauteur, PhD
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Dr. BioPharma Dive: Altasciences' Comprehensive Integrated Solution for Clinical Supply ManufactureClinical Applications of Hallucinogens, Dissociatives and Other Schedule I Drugs
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Following an initial period of study, mainly in the early 20th century, many hallucinogenic drugs had been dismissed as drugs of abuse with no clinical utility. Saving You Time With Tell Us Once™
BioPharma Dive: Ligand Binding Program Considerations — The Value of Preclinical to Clinical Bioanalytical ExpertiseSnuggle Wrap-based Restraint Method of Continuous Infusion in Juvenile Nonhuman Primates
Historical Control Database of Cynomolgus Macaque Spermatozoa
Determination of Normal: Flow Cytometry Analysis of Major Immune Cell Populations in Peripheral Blood of Naïve Cynomolgus Monkeys
|